olodaterol   Click here for help

GtoPdb Ligand ID: 7543

Synonyms: BI-1744 | BI-1744-CL | Striverdi®
Approved drug Immunopharmacology Ligand
olodaterol is an approved drug (FDA (2014))
Compound class: Synthetic organic
Comment: Marketed formulations may contain olodaterol hydrochloride (PubChem CID 11711522).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: olodaterol

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 100.05
Molecular weight 386.18
XLogP 1.81
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1ccc(cc1)CC(NCC(c1cc(O)cc2c1OCC(=O)N2)O)(C)C
Isomeric SMILES COc1ccc(cc1)CC(NC[C@@H](c1cc(O)cc2c1OCC(=O)N2)O)(C)C
InChI InChI=1S/C21H26N2O5/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26)/t18-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Olodaterol was approved by the FDA in July 2014 as an inhalation medication for the treatment of chronic obstructive pulmonary disease (COPD). Phase 2 trials have also been conducted in patients with asthma (see NCT01013753).
This drug has been further assessed in clinical trials in combination with the muscarinic antagonist tiotropium bromide (also a bronchodilator).
In May 2015 the US FDA approved a fixed-dose combination of tiotropium bromide and olodaterol (Stiolto Respimat®) as 'a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema' Drugs.com.
Click here to view a full list of associated trials registered with ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Olodaterol is a long acting β-adrenoceptor agonist (LABA) acting on β2-ARs in the lung to cause bronchodilation which improves airway function. Olodaterol appears to have low intrinsic β1-AR action, thereby limiting cardiac side effects [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01013753 A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma. Phase 2 Interventional Boehringer Ingelheim
External links Click here for help